Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Exagen Inc (NASDAQ: XGN) closed at $8.4 in the last session, down -2.67% from day before closing price of $8.63. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 0.52 million shares were traded. XGN stock price reached its highest trading level at $8.87 during the session, while it also had its lowest trading level at $8.37.
Ratios:
We take a closer look at XGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.59 and its Current Ratio is at 4.95. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 23, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when NMSIC Co-Investment Fund, L.P. sold 350,000 shares for $3.30 per share. The transaction valued at 1,155,000 led to the insider holds 1,758,958 shares of the business.
NMSIC Co-Investment Fund, L.P. sold 200,000 shares of XGN for $660,040 on Nov 20 ’24. The 10% Owner now owns 2,108,958 shares after completing the transaction at $3.30 per share. On Nov 15 ’24, another insider, Black Jeffrey G., who serves as the Chief Financial Officer of the company, bought 22,298 shares for $2.98 each. As a result, the insider paid 66,448 and bolstered with 274,492 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XGN now has a Market Capitalization of 183629024 and an Enterprise Value of 180092592. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.14 while its Price-to-Book (P/B) ratio in mrq is 8.79. Its current Enterprise Value per Revenue stands at 3.06 whereas that against EBITDA is -14.644.
Stock Price History:
The Beta on a monthly basis for XGN is 1.63, which has changed by 3.1176472 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, XGN has reached a high of $9.10, while it has fallen to a 52-week low of $1.78. The 50-Day Moving Average of the stock is 18.34%, while the 200-Day Moving Average is calculated to be 73.12%.
Shares Statistics:
According to the various share statistics, XGN traded on average about 337.66K shares per day over the past 3-months and 603420 shares per day over the past 10 days. A total of 22.00M shares are outstanding, with a floating share count of 13.53M. Insiders hold about 38.53% of the company’s shares, while institutions hold 28.07% stake in the company. Shares short for XGN as of 1752537600 were 922602 with a Short Ratio of 2.73, compared to 1749772800 on 204880. Therefore, it implies a Short% of Shares Outstanding of 922602 and a Short% of Float of 5.1799998.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.07 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.65 and -$0.75 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.32, with 5.0 analysts recommending between -$0.21 and -$0.4.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $16.95M. It ranges from a high estimate of $17.6M to a low estimate of $16.5M. As of the current estimate, Exagen Inc’s year-ago sales were $12.51MFor the next quarter, 6 analysts are estimating revenue of $17.58M. There is a high estimate of $18.2M for the next quarter, whereas the lowest estimate is $17.2M.
A total of 6 analysts have provided revenue estimates for XGN’s current fiscal year. The highest revenue estimate was $68.46M, while the lowest revenue estimate was $66.5M, resulting in an average revenue estimate of $67.21M. In the same quarter a year ago, actual revenue was $55.64MBased on 7 analysts’ estimates, the company’s revenue will be $76.13M in the next fiscal year. The high estimate is $77.6M and the low estimate is $73.97M.
